The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22

A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22
A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22
Background: High risk stage I NSGCT is characterised by vascular or lymphatic invasion within the primary tumour. This group comprises ~50% of stage I pts with, (untreated) a relapse rate of 35-40%. Options for the management of such pts include adjuvant chemotherapy, retroperitoneal lymph node dissection (± adjuvant chemotherapy) and surveillance, each achieving similarly high cure rates. An FDG PET scan may be able to aid discrimination between pts without occult metastatic disease, for whom surveillance is an attractive option, and those requiring immediate therapy.
Methods: High risk (vascular invasion +ve) CS1 NSGCT pts underwent FDG PET scanning within ~8 weeks of orchidectomy. PET+ve pts went off study, PET -ve pts were followed on surveillance. The primary outcome measure was the -ve predictive value of PET, defined as the 2-year relapse-free rate (RFR) in pts with a negative PET scan. Assuming a RFR of ~90%, to exclude a RFR < 80% with 80% power (5% significance), ~100 PET negative pts were required from ~135 scanned pts. All baseline CT scans were subject to central review blinded to PET result and relapse status and, in relapsed pts, a retrospective comparison of the CT and PET scan results.
Results: Pts were registered between 5/02 and 1/05, when the trial was stopped early by the independent Data Monitoring Committee due to an unacceptably high relapse rate in the PET-ve pts. 116 pts were registered of whom 111 underwent PET scans. 88 pts (79%) were PET-ve; 87 proceeded to surveillance and one requested adjuvant chemotherapy. With median follow-up of 11 months, 33 of the 87 pts on surveillance relapsed for a one-year relapse-free rate of 63% 90% CI (54%, 72%). The PET +ve/relapse rate was 69% in patients with normal markers pre-orchidectomy (n = 36) and 41% in those with raised markers (n = 66). There has been one death (suicide) amongst the PET -ve pts. The radiology and PET scan review will be completed by May 2006.
Conclusions: Though PET identified a proportion of pts with disease not detected by CT scan the relapse rate amongst PET -ve pts remains high. The study results therefore suggest that 18FDG PET scanning is not able to identify pts at sufficiently low risk of relapse to replace other treatment options in this setting.
time, pet, cancer, risk, trial, patient, prediction, high-risk, cell
1359-6349
4520
Huddart, R.
76d2b300-d66c-4b49-8bee-47755651a4a8
O'Doherty, M.
11913caf-f154-4aad-ba0e-48651ef7483c
Padhani, A.
25ebb281-c05f-45c3-b379-ddafe38b3541
Rustin, G.
fe49659a-bc70-47a4-88f6-db232221a034
Mead, G.
a01f4764-abab-4ccb-804f-0b6f8d4d7696
Seiby, P.
19716987-148f-429c-ba03-7e6a530ec1d1
Vasey, P.
5281eaca-4f4d-48dd-896c-ba83f15e9393
Wow, M.
6b127e67-72ad-4d1a-b898-88f62e7af659
Kirk, S.
19df0e0e-bbf3-4ed1-98ca-106a8aecb413
Stenning, S.
55e998a7-e762-4d38-a3d8-288728395aaf
Huddart, R.
76d2b300-d66c-4b49-8bee-47755651a4a8
O'Doherty, M.
11913caf-f154-4aad-ba0e-48651ef7483c
Padhani, A.
25ebb281-c05f-45c3-b379-ddafe38b3541
Rustin, G.
fe49659a-bc70-47a4-88f6-db232221a034
Mead, G.
a01f4764-abab-4ccb-804f-0b6f8d4d7696
Seiby, P.
19716987-148f-429c-ba03-7e6a530ec1d1
Vasey, P.
5281eaca-4f4d-48dd-896c-ba83f15e9393
Wow, M.
6b127e67-72ad-4d1a-b898-88f62e7af659
Kirk, S.
19df0e0e-bbf3-4ed1-98ca-106a8aecb413
Stenning, S.
55e998a7-e762-4d38-a3d8-288728395aaf

Huddart, R., O'Doherty, M., Padhani, A., Rustin, G., Mead, G., Seiby, P., Vasey, P., Wow, M., Kirk, S. and Stenning, S. (2005) A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. EJC Supplements, 24 (18S), 4520.

Record type: Article

Abstract

Background: High risk stage I NSGCT is characterised by vascular or lymphatic invasion within the primary tumour. This group comprises ~50% of stage I pts with, (untreated) a relapse rate of 35-40%. Options for the management of such pts include adjuvant chemotherapy, retroperitoneal lymph node dissection (± adjuvant chemotherapy) and surveillance, each achieving similarly high cure rates. An FDG PET scan may be able to aid discrimination between pts without occult metastatic disease, for whom surveillance is an attractive option, and those requiring immediate therapy.
Methods: High risk (vascular invasion +ve) CS1 NSGCT pts underwent FDG PET scanning within ~8 weeks of orchidectomy. PET+ve pts went off study, PET -ve pts were followed on surveillance. The primary outcome measure was the -ve predictive value of PET, defined as the 2-year relapse-free rate (RFR) in pts with a negative PET scan. Assuming a RFR of ~90%, to exclude a RFR < 80% with 80% power (5% significance), ~100 PET negative pts were required from ~135 scanned pts. All baseline CT scans were subject to central review blinded to PET result and relapse status and, in relapsed pts, a retrospective comparison of the CT and PET scan results.
Results: Pts were registered between 5/02 and 1/05, when the trial was stopped early by the independent Data Monitoring Committee due to an unacceptably high relapse rate in the PET-ve pts. 116 pts were registered of whom 111 underwent PET scans. 88 pts (79%) were PET-ve; 87 proceeded to surveillance and one requested adjuvant chemotherapy. With median follow-up of 11 months, 33 of the 87 pts on surveillance relapsed for a one-year relapse-free rate of 63% 90% CI (54%, 72%). The PET +ve/relapse rate was 69% in patients with normal markers pre-orchidectomy (n = 36) and 41% in those with raised markers (n = 66). There has been one death (suicide) amongst the PET -ve pts. The radiology and PET scan review will be completed by May 2006.
Conclusions: Though PET identified a proportion of pts with disease not detected by CT scan the relapse rate amongst PET -ve pts remains high. The study results therefore suggest that 18FDG PET scanning is not able to identify pts at sufficiently low risk of relapse to replace other treatment options in this setting.

This record has no associated files available for download.

More information

Published date: 20 June 2005
Keywords: time, pet, cancer, risk, trial, patient, prediction, high-risk, cell

Identifiers

Local EPrints ID: 62791
URI: http://eprints.soton.ac.uk/id/eprint/62791
ISSN: 1359-6349
PURE UUID: 6a5a4cd5-3641-4cc4-9bd2-4a58b4058b21

Catalogue record

Date deposited: 11 Sep 2008
Last modified: 11 Dec 2021 18:09

Export record

Contributors

Author: R. Huddart
Author: M. O'Doherty
Author: A. Padhani
Author: G. Rustin
Author: G. Mead
Author: P. Seiby
Author: P. Vasey
Author: M. Wow
Author: S. Kirk
Author: S. Stenning

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×